| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
Departments of 1 Gynecologic Oncology, 2 Experimental Therapeutics, 3 Cancer Biology, and 4 Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Requests for reprints: Anil K. Sood, Departments of Gynecologic Oncology and Cancer Biology, The University of Texas M.D. Anderson Cancer Center, 1155 Herman Pressler, CPB6.3244, Unit 1362, Houston, TX 77030. Phone: 713-745-5266; Fax: 713-792-7586; E-mail: asood{at}mdanderson.org.
Inducing destruction of specific mRNA using small interfering RNA (siRNA) is a powerful tool in analysis of protein function, but its use as a therapeutic modality has been limited by inefficient or impractical delivery systems. We have used siRNA incorporated into the neutral liposome 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) for efficient in vivo siRNA delivery. In nude mice bearing i.p. ovarian tumors, nonsilencing siRNA tagged with the fluorochrome Alexa 555 was encapsulated into DOPC liposomes and shown to be taken up by the tumor as well as many major organs. Furthermore, DOPC-encapsulated siRNA targeting the oncoprotein EphA2 was highly effective in reducing in vivo EphA2 expression 48 hours after a single dose as measured by both Western blot and immunohistochemistry. Therapy experiments in an orthotopic mouse model of ovarian cancer were initiated 1 week after injection of either HeyA8 or SKOV3ip1 cell lines. Three weeks of treatment with EphA2-targeting siRNA-DOPC (150 µg/kg twice weekly) reduced tumor growth when compared with a nonsilencing siRNA (SKOV3ip1: 0.35 versus 0.70 g; P = 0.020; HeyA8: 0.98 versus 1.51 g; P = 0.16). When EphA2-targeting siRNA-DOPC was combined with paclitaxel, tumor growth was dramatically reduced compared with treatment with paclitaxel and a nonsilencing siRNA (SKOV3ip1: 0.04 versus 0.22 g; P < 0.001; HeyA8: 0.21 versus 0.84 g; P = 0.0027). These studies show the feasibility of siRNA as a clinically applicable therapeutic modality.
This article has been cited by other articles:
![]() |
S. Jiang, M. K. Gnanasammandhan, and Y. Zhang Optical imaging-guided cancer therapy with fluorescent nanoparticles J R Soc Interface, January 6, 2010; 7(42): 3 - 18. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Brannan, W. Dong, L. Prudkin, C. Behrens, R. Lotan, B. N. Bekele, I. Wistuba, and F. M. Johnson Expression of the Receptor Tyrosine Kinase EphA2 Is Increased in Smokers and Predicts Poor Survival in Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2009; 15(13): 4423 - 4430. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. CHHABRA, A. VERMA, and K. MEHTA Tissue Transglutaminase Promotes or Suppresses Tumors Depending on Cell Context Anticancer Res, June 1, 2009; 29(6): 1909 - 1919. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Mangala, V. Zuzel, R. Schmandt, E. S. Leshane, J. B. Halder, G. N. Armaiz-Pena, W. A. Spannuth, T. Tanaka, M. M.K. Shahzad, Y. G. Lin, et al. Therapeutic Targeting of ATP7B in Ovarian Carcinoma Clin. Cancer Res., June 1, 2009; 15(11): 3770 - 3780. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-W. Lee, M. M.K. Shahzad, Y. G. Lin, G. Armaiz-Pena, L. S. Mangala, H.-D. Han, H.-S. Kim, E. J. Nam, N. B. Jennings, J. Halder, et al. Surgical Stress Promotes Tumor Growth in Ovarian Carcinoma Clin. Cancer Res., April 15, 2009; 15(8): 2695 - 2702. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kobel, C. B. Gilks, D. G. Huntsman, W. M. Merritt, D. L. Urbauer, and A. K. Sood Dicer and Drosha in Ovarian Cancer N. Engl. J. Med., March 12, 2009; 360(11): 1150 - 1151. [Full Text] [PDF] |
||||
![]() |
M. Parri, M. L. Taddei, F. Bianchini, L. Calorini, and P. Chiarugi EphA2 Reexpression Prompts Invasion of Melanoma Cells Shifting from Mesenchymal to Amoeboid-like Motility Style Cancer Res., March 1, 2009; 69(5): 2072 - 2081. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Merritt, Y. G. Lin, L. Y. Han, A. A. Kamat, W. A. Spannuth, R. Schmandt, D. Urbauer, L. A. Pennacchio, J.-F. Cheng, A. M. Nick, et al. Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer N. Engl. J. Med., December 18, 2008; 359(25): 2641 - 2650. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Aleku, P. Schulz, O. Keil, A. Santel, U. Schaeper, B. Dieckhoff, O. Janke, J. Endruschat, B. Durieux, N. Roder, et al. Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Cancer Res., December 1, 2008; 68(23): 9788 - 9798. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wykosky and W. Debinski The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting Mol. Cancer Res., December 1, 2008; 6(12): 1795 - 1806. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Villares, M. Zigler, H. Wang, V. O. Melnikova, H. Wu, R. Friedman, M. C. Leslie, P. E. Vivas-Mejia, G. Lopez-Berestein, A. K. Sood, et al. Targeting Melanoma Growth and Metastasis with Systemic Delivery of Liposome-Incorporated Protease-Activated Receptor-1 Small Interfering RNA Cancer Res., November 1, 2008; 68(21): 9078 - 9086. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. G. Lin, A. Immaneni, W. M. Merritt, L. S. Mangala, S. W. Kim, M. M.K. Shahzad, Y. T.M. Tsang, G. N. Armaiz-Pena, C. Lu, A. A. Kamat, et al. Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth Clin. Cancer Res., September 1, 2008; 14(17): 5437 - 5446. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Y. Hwang, L. S. Mangala, J. Y. Fok, Y. G. Lin, W. M. Merritt, W. A. Spannuth, A. M. Nick, D. J. Fiterman, P. E. Vivas-Mejia, M. T. Deavers, et al. Clinical and Biological Significance of Tissue Transglutaminase in Ovarian Carcinoma Cancer Res., July 15, 2008; 68(14): 5849 - 5858. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Soni, A. Akcakanat, G. Singh, D. Luyimbazi, Y. Zheng, D. Kim, A. Gonzalez-Angulo, and F. Meric-Bernstam eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling Mol. Cancer Ther., July 1, 2008; 7(7): 1782 - 1788. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Yang, S. R. Hamilton, A. Sood, T. Kuwai, L. Ellis, A. Sanguino, G. Lopez-Berestein, and D. D. Boyd The Previously Undescribed ZKSCAN3 (ZNF306) Is a Novel "Driver" of Colorectal Cancer Progression Cancer Res., June 1, 2008; 68(11): 4321 - 4330. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Verma, S. Guha, P. Diagaradjane, A. B. Kunnumakkara, A. M. Sanguino, G. Lopez-Berestein, A. K. Sood, B. B. Aggarwal, S. Krishnan, J. G. Gelovani, et al. Therapeutic Significance of Elevated Tissue Transglutaminase Expression in Pancreatic Cancer Clin. Cancer Res., April 15, 2008; 14(8): 2476 - 2483. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Merritt, Y. G. Lin, W. A. Spannuth, M. S. Fletcher, A. A. Kamat, L. Y. Han, C. N. Landen, N. Jennings, K. De Geest, R. R. Langley, et al. Effect of Interleukin-8 Gene Silencing With Liposome-Encapsulated Small Interfering RNA on Ovarian Cancer Cell Growth J Natl Cancer Inst, March 5, 2008; 100(5): 359 - 372. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. N. Landen Jr, M. J. Birrer, and A. K. Sood Early Events in the Pathogenesis of Epithelial Ovarian Cancer J. Clin. Oncol., February 20, 2008; 26(6): 995 - 1005. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Gray, G. Van Buren, N. A. Dallas, L. Xia, X. Wang, A. D. Yang, R. J. Somcio, Y. G. Lin, S. Lim, F. Fan, et al. Therapeutic Targeting of Neuropilin-2 on Colorectal Carcinoma Cells Implanted in the Murine Liver J Natl Cancer Inst, January 16, 2008; 100(2): 109 - 120. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Halder, Y. G. Lin, W. M. Merritt, W. A. Spannuth, A. M. Nick, T. Honda, A. A. Kamat, L. Y. Han, T. J. Kim, C. Lu, et al. Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma Cancer Res., November 15, 2007; 67(22): 10976 - 10983. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. N. Landen Jr., Y. G. Lin, G. N. Armaiz Pena, P. D. Das, J. M. Arevalo, A. A. Kamat, L. Y. Han, N. B. Jennings, W. A. Spannuth, P. H. Thaker, et al. Neuroendocrine Modulation of Signal Transducer and Activator of Transcription-3 in Ovarian Cancer Cancer Res., November 1, 2007; 67(21): 10389 - 10396. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Nilsson, G. Armaiz-Pena, R. Takahashi, Y. G. Lin, J. Trevino, Y. Li, N. Jennings, J. Arevalo, S. K. Lutgendorf, G. E. Gallick, et al. Stress Hormones Regulate Interleukin-6 Expression by Human Ovarian Carcinoma Cells through a Src-dependent Mechanism J. Biol. Chem., October 12, 2007; 282(41): 29919 - 29926. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. N. Landen Jr., Y. G. Lin, A. Immaneni, M. T. Deavers, W. M. Merritt, W. A. Spannuth, D. C. Bodurka, D. M. Gershenson, W. R. Brinkley, and A. K. Sood Overexpression of the Centrosomal Protein Aurora-A Kinase is Associated with Poor Prognosis in Epithelial Ovarian Cancer Patients Clin. Cancer Res., July 15, 2007; 13(14): 4098 - 4104. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. G. Lin, A. B. Kunnumakkara, A. Nair, W. M. Merritt, L. Y. Han, G. N. Armaiz-Pena, A. A. Kamat, W. A. Spannuth, D. M. Gershenson, S. K. Lutgendorf, et al. Curcumin Inhibits Tumor Growth and Angiogenesis in Ovarian Carcinoma by Targeting the Nuclear Factor-{kappa}B Pathway Clin. Cancer Res., June 1, 2007; 13(11): 3423 - 3430. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Hammond, R. Lutterbuese, S. Roff, P. Lutterbuese, B. Schlereth, E. Bruckheimer, M. S. Kinch, S. Coats, P. A. Baeuerle, P. Kufer, et al. Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct Cancer Res., April 15, 2007; 67(8): 3927 - 3935. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Wright and D. G. Mutch Getting the Message Out: RNA Interference of Human Papillomavirus Reproductive Sciences, January 1, 2007; 14(1): 6 - 7. [PDF] |
||||
![]() |
C. N. Landen Jr., C. Lu, L. Y. Han, K. T. Coffman, E. Bruckheimer, J. Halder, L. S. Mangala, W. M. Merritt, Y. G. Lin, C. Gao, et al. Efficacy and Antivascular Effects of EphA2 Reduction With an Agonistic Antibody in Ovarian Cancer. J Natl Cancer Inst, November 1, 2006; 98(21): 1558 - 1570. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Halder, A. A. Kamat, C. N. Landen Jr., L. Y. Han, S. K. Lutgendorf, Y. G. Lin, W. M. Merritt, N. B. Jennings, A. Chavez-Reyes, R. L. Coleman, et al. Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy. Clin. Cancer Res., August 15, 2006; 12(16): 4916 - 4924. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Sood, C. N. Landen, A. Sanguino, and G. Lopez-Berestein Therapeutic gene silencing in vivo using RNA interference Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 353 - 358. [Full Text] [PDF] |
||||
![]() |
A. A. Kamat, M. Fletcher, L. M. Gruman, P. Mueller, A. Lopez, C. N. Landen Jr., L. Han, D. M. Gershenson, and A. K. Sood The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer Clin. Cancer Res., March 15, 2006; 12(6): 1707 - 1714. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Hickson, D. Huo, D. J. Vander Griend, A. Lin, C. W. Rinker-Schaeffer, and S. D. Yamada The p38 Kinases MKK4 and MKK6 Suppress Metastatic Colonization in Human Ovarian Carcinoma Cancer Res., February 15, 2006; 66(4): 2264 - 2270. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |